Processa Pharmaceuticals, Inc. (PCSA)
PCSA Stock Price Chart
Explore Processa Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze PCSA price movements and trends.
PCSA Company Profile
Discover essential business fundamentals and corporate details for Processa Pharmaceuticals, Inc. (PCSA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Mar 2014
Employees
10.00
CEO
George K. Ng
Description
Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The company's leading investigational drug, PCS499, is an oral tablet presently undergoing Phase 2B clinical assessment. It aims to treat both ulcerative and non-ulcerative manifestations of necrobiosis lipoidica, a chronic and disfiguring dermatological condition. Processa's portfolio also features PCS12852, a unique selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. This compound is currently in Phase 2A clinical trials for its potential application in managing gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia. Furthermore, the firm is advancing PCS3117, a cytosine analog, which has reached Phase 2B clinical trials for its use in pancreatic cancer and non-small cell lung cancer. Another candidate, PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase, is progressing through Phase 1B clinical trials for metastatic colorectal and breast cancers. In addition, Processa is developing PCS11T, an analog derived from the drugs SN38 and irinotecan, intended for the treatment of diverse cancer types. The company was founded in 2011 and maintains its corporate headquarters in Hanover, Maryland.
PCSA Financial Timeline
Browse a chronological timeline of Processa Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$1.00.
Earnings released on 7 May 2026
EPS came in at -$1.29 falling short of the estimated -$1.00 by -29.00%.
Earnings released on 19 Mar 2026
EPS came in at -$18.50 falling short of the estimated -$1.50 by -1.13k%.
Stock split effective on 17 Dec 2025
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 6 Nov 2025
EPS came in at -$1.75 surpassing the estimated -$2.00 by +12.50%.
Earnings released on 7 Aug 2025
EPS came in at -$6.25 falling short of the estimated -$5.75 by -8.70%.
Earnings released on 8 May 2025
EPS came in at -$7.50 surpassing the estimated -$19.25 by +61.04%.
Earnings released on 20 Mar 2025
EPS came in at -$18.50 falling short of the estimated -$0.76 by -2.33k%.
Earnings released on 30 Oct 2024
EPS came in at -$1.03 falling short of the estimated -$1.00 by -3.00%.
Earnings released on 13 Aug 2024
EPS came in at -$1.01 falling short of the estimated -$0.98 by -3.06%.
Earnings released on 10 May 2024
EPS came in at -$1.11 surpassing the estimated -$1.18 by +5.93%.
Earnings released on 29 Mar 2024
EPS came in at -$0.24 surpassing the estimated -$1.60 by +85.00%.
Stock split effective on 22 Jan 2024
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Nov 2023
EPS came in at -$1.60 falling short of the estimated -$0.10 by -1.50k%.
Earnings released on 10 Aug 2023
EPS came in at -$2.00 surpassing the estimated -$3.00 by +33.33%.
Earnings released on 15 May 2023
EPS came in at -$3.60 surpassing the estimated -$5.60 by +35.71%.
Earnings released on 30 Mar 2023
EPS came in at -$7.00 falling short of the estimated -$5.00 by -40.00%.
Earnings released on 8 Nov 2022
EPS came in at -$7.40 falling short of the estimated -$6.80 by -8.82%.
Earnings released on 12 Aug 2022
EPS came in at -$6.40 falling short of the estimated -$0.20 by -3.10k%.
Earnings released on 12 May 2022
EPS came in at -$4.00 surpassing the estimated -$4.80 by +16.67%.
Earnings released on 30 Mar 2022
EPS came in at -$4.20 falling short of the estimated -$3.60 by -16.67%.
Earnings released on 12 Nov 2021
EPS came in at -$3.80 surpassing the estimated -$4.20 by +9.52%.
Earnings released on 12 Aug 2021
EPS came in at -$4.00 falling short of the estimated -$3.00 by -33.33%.
PCSA Stock Performance
Access detailed PCSA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
